0.00Open0.05Pre Close0 Volume435 Open Interest7.50Strike Price0.00Turnover2532.54%IV5.10%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.2250Delta0.7981Gamma157.00Leverage Ratio-42.8260Theta0.0000Rho-35.33Eff Leverage0.0000Vega
Avadel Pharmaceuticals Stock Discussion
Avadel's key product, LUMRYZ, is approved by the U.S. Food and Drug Administration (FDA). LUMRYZ features a unique once-nightly formulation, making it the first and only medication of its kind. In c...
AVDL fell 25.2% to $8 shortly before 5 p.m. ET after the company announced that Q4 revenues will come in at $50 million – below the $52.7 million that analysts had reportedly expected.
The company like...
yeah, cluster buys drew my attention too
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challen...
🎃⚡️🎃
📊⚡️📊
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy
No comment yet